Global Polymyalgia Rheumatica Treatment Market, By Drug Class (Corticosteroids, Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2029.
Polymyalgia Rheumatica Treatment Market Analysis and Size
The global polymyalgia rheumatica treatment market is expected to witness significant growth during the forecast period. This disorder mainly occurs in ageing people aged above 60 years. It is more dominant in females than males, with a ratio of 2:1. Polymyalgia rheumatica is an autoimmune disease with no identified cause, however its been suggested that there is a link between genetic and environmental factors leading to the spread of this condition. Sudden outbreak of the COVID-19 pandemic imposed stringent lockdown regulations globally, causing interruptions in import and export activities of global mucormycosis market.
Data Bridge Market Research analyses a growth rate in the global polymyalgia rheumatica treatment market in the forecast period 2022-2029. The expected CAGR of global polymyalgia rheumatica treatment market is tend to be around 14% in the mentioned forecast period. The market was valued at USD 180 million in 2021, and it would grow upto USD 513.47 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Polymyalgia rheumatica is a type of inflammatory disorder which causes inflammation, stiffness and muscle pain around the shoulders, neck and hips. It is prompted by numerous factors such as genetic and environmental factors. Polymyalgia rheumatica is often related with giant cell arteritis (GCA). This situation results in increased swelling of arteries in head, which can lead to blurred vision and headaches. This disease prevalence is rising and important diagnostic procedures and treatments will boost the growth of the market.
Polymyalgia Rheumatica Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Class (Corticosteroids, Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (U.S.), Lilly (U.S.), Amgen Inc. (U.S.), PuraCap Pharmaceutical LLC (U.S.), Glenmark Pharmaceuticals Limited (India)
|
|
Market Opportunities
|
|
Global Polymyalgia Rheumatica Treatment Market Dynamics
Drivers
- Extensive Use Of Medications
The condition of polymyalgia is usually treated with certain medications such as corticosteroids to ease symptoms and uneasiness. Steroids are quite helpful as it can ease pain and stiffness in a few days. Although, the use of the drug requires widespread monitoring as it can cause serious side effects, such as loss of bone density, cataracts, and high blood pressure. This can convert to routine diagnostic tests to monitor the effect and treatment of the disease, thus boosting the the market growth.
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the global polymyalgia rheumatic treatment market. To encourage researchers and pharmaceutical companies to develop novel medicines, the government is funding research and development (R&D) initiatives.
Opportunities
- Increased Advanced Diagnostic Technology
Growing research on polymyalgia rheumatica to understand and study its association with musculoskeletal symptoms is expected to expand the market growth. The introduction of several advanced diagnostic technologies to analyse several conditions boost the industry growth. Furthermore, technological advancements in imaging tests such as magnetic resonance imaging (MRI) are reducing its scorer bias to diagnose the disease efficiently. MRI can detect asymptomatic cases of polymyalgia rheumatica, hence it is increasing the demand for its treatment. All these factors are also contributing in the growth of the market.
- Increase in Elderly Population
Life expectancy is growing around the world, which has led to an increase in the aging population. This trend positively impacts the industry by increasing the incidence of the disease and creating per capita demand for its remedies.
Restraints/Challenges
- Lack of skilled professionals
The lack of qualified personnel who are unable to perform these treatments could curb the growth of the global polymyalgia rheumatica treatment market over a forecast period.
- Unavailability of Appropriate Treatments
To treat conditions which are rare, many a times all treatments are not available, especially in the under-developed countries. The severe patients needs to be treated with the advanced techniques but at times, these are not available in the hospitals and clinics. Thus, it hampers the market growth.
This global polymyalgia rheumatica treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global polymyalgia rheumatica treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Polymyalgia Rheumatica Treatment Market Scope
The global polymyalgia rheumatica treatment market is segmented on the basis of drug class, fungi type, route of administration,end-user, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- Corticosteroids
- Disease-Modifying Anti-Rheumatic Drugs (DMARDS)
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Polymyalgia Rheumatica Treatment Market Regional Analysis/Insights
The global polymyalgia rheumatica treatment market is analysed and market size insights and trends are provided by drug class, fungi type, route of administration,end-user, distribution channel as referenced above.
The major countries covered in the global polymyalgia rheumatica treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is considered to have the highest lucrative growth in the forecast period due to the high prevalence of polymyalgia rheumatica and the presence of sophisticated medical facilities to optimize the treatment for patients suffering from the polymyalgia rheumatica.
Asia-Pacific is dominating the market due to the developing healthcare facilities, large number of generic manufacturer and rise in government initiatives and specialist communities.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Polymyalgia Rheumatica Treatment Market Share Analysis
The global polymyalgia rheumatica treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global polymyalgia rheumatica treatment market.
Key players operating in the global polymyalgia rheumatica treatment market include:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Merck & Co., Inc. (U.S.)
- Lilly (U.S.)
- Amgen Inc. (U.S.)
- PuraCap® Pharmaceutical LLC (U.S.)
- Glenmark Pharmaceuticals Limited (India)
SKU-